Nektar Therapeutics

NKTR

$56.56

Name : Nektar Therapeutics

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $1,075,690,496.00

EPSttm : -8.64

Nektar Therapeutics

$56.56

2.48%

$1.44

Float Short %

8.64

Margin Of Safety %

Put/Call OI Ratio

0.62

EPS Next Q Diff

-0.17

EPS Last/This Y

-2.36

EPS This/Next Y

-0.95

Price

56.51

Target Price

104.5

Analyst Recom

1.75

Performance Q

125.34

Relative Volume

1.01

Beta

-1.16

Ticker: NKTR

21 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-09-09	NKTR	48.55	0.69	0.92	37743
2025-09-10	NKTR	48.16	0.73	0.14	39099
2025-09-11	NKTR	47.13	0.68	0.39	41299
2025-09-12	NKTR	48.84	0.68	0.23	43228
2025-09-15	NKTR	49.09	0.66	0.59	44562
2025-09-16	NKTR	49.69	0.66	0.29	45772
2025-09-17	NKTR	51.07	0.60887015177066	0.25520671433012	47703
2025-09-18	NKTR	58.74	0.58	0.33	48838
2025-09-22	NKTR	59.21	0.58	2.93	38432
2025-09-23	NKTR	59.3	0.55	1.30	38656
2025-09-24	NKTR	60.49	0.59	0.17	39568
2025-09-25	NKTR	55.55	0.58	0.46	41808
2025-09-26	NKTR	58.58	0.62	0.44	42892
2025-09-29	NKTR	58.92	0.62	0.19	43314
2025-09-30	NKTR	56.86	0.64	0.42	44300
2025-10-01	NKTR	58.59	0.62	0.42	45317
2025-10-02	NKTR	59.94	0.61	0.40	45640
2025-10-03	NKTR	60.24	0.61	0.24	46563
2025-10-06	NKTR	59.78	0.62	0.09	47946
2025-10-07	NKTR	58.6	0.61	0.23	48964
2025-10-08	NKTR	56.5	0.62	0.15	50044
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

21 items 1 of 1

22 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-09-09	NKTR	48.55	-5.5	-	-11.06
2025-09-10	NKTR	48.15	-5.5	-	-11.06
2025-09-11	NKTR	47.20	-5.5	-	-11.06
2025-09-12	NKTR	48.72	-5.5	-	-11.06
2025-09-15	NKTR	49.04	-5.5	-	-11.06
2025-09-16	NKTR	49.89	-5.5	-	-11.06
2025-09-17	NKTR	51.06	-5.5	-	-11.06
2025-09-18	NKTR	58.75	-5.5	-	-11.06
2025-09-19	NKTR	55.06	-5.5	-	-11.06
2025-09-22	NKTR	58.89	-5.5	-	-11.06
2025-09-23	NKTR	59.58	-5.5	-	-11.06
2025-09-24	NKTR	60.26	-5.5	-	-11.06
2025-09-25	NKTR	55.62	-5.5	-	-11.06
2025-09-26	NKTR	58.50	-5.5	-	-11.06
2025-09-29	NKTR	59.03	-5.5	-	-11.06
2025-09-30	NKTR	56.86	-5.5	-	-11.06
2025-10-01	NKTR	58.80	-5.5	-	-11.06
2025-10-02	NKTR	60.45	-5.5	-	-11.06
2025-10-03	NKTR	60.43	-5.5	-	-11.06
2025-10-06	NKTR	59.94	-5.5	-	-11.06
2025-10-07	NKTR	57.94	-5.5	-	-11.06
2025-10-08	NKTR	56.51	-5.5	-	-11.06
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

22 items 1 of 1

22 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-09-09	NKTR	-11.44	12.34	5.58
2025-09-10	NKTR	-11.48	12.34	5.58
2025-09-11	NKTR	-11.48	12.34	6.02
2025-09-12	NKTR	-12.56	12.34	6.00
2025-09-15	NKTR	-14.01	13.85	6.00
2025-09-16	NKTR	-14.01	13.85	6.00
2025-09-17	NKTR	-14.23	13.85	6.00
2025-09-18	NKTR	-14.23	13.85	6.00
2025-09-19	NKTR	-14.23	13.85	6.00
2025-09-22	NKTR	-14.23	13.84	6.00
2025-09-23	NKTR	-14.23	13.84	6.00
2025-09-24	NKTR	-14.23	13.84	6.00
2025-09-25	NKTR	-14.23	13.84	8.64
2025-09-26	NKTR	-14.23	13.84	8.64
2025-09-29	NKTR	-14.23	13.92	8.64
2025-09-30	NKTR	-14.28	13.92	8.64
2025-10-01	NKTR	-14.28	13.92	8.64
2025-10-02	NKTR	-14.28	13.92	8.64
2025-10-03	NKTR	-14.28	13.92	8.64
2025-10-06	NKTR	-14.28	-1.30	8.64
2025-10-07	NKTR	-14.28	-1.30	8.64
2025-10-08	NKTR	-14.28	-1.30	8.64
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

22 items 1 of 1

Last Quarter Act. EPS

-2.95

Avg. EPS Est. Current Quarter

-2.8

Avg. EPS Est. Next Quarter

-3.12

Insider Transactions

-14.28

Institutional Transactions

-1.3

Beta

-1.16

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

85.9

Max Drawdown 5-Year %

-98.3

Target Price

104.5

P/E

Forward P/E

PEG

P/S

14.36

P/B

P/Free Cash Flow

EPS

-8.72

Average EPS Est. Cur. Y

-11.06

EPS Next Y. (Est.)

-12.02

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-163.17

Relative Volume

1.01

Return on Equity vs Sector %

479.8

Return on Equity vs Industry %

493.5

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.38

EBIT Estimation

Nektar Therapeutics

Sector: Healthcare

Industry: Biotechnology

Employees: 61

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset is a bivalent antibody molecule used to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling; and NKTR-255, an IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

stock quote shares NKTR – Nektar Therapeutics Stock Price stock today

news today NKTR – Nektar Therapeutics stock forecast ,stock prediction 2023 2024 2025

marketwatch NKTR – Nektar Therapeutics yahoo finance google finance

stock history NKTR – Nektar Therapeutics invest stock market

stock prices NKTR premarket after hours

ticker NKTR fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: NKTR

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y